



MICHAEL ANDERSON

BIOTECHNOLOGY IP COUNSEL

CONTACT

-  (555) 234-5678
-  michael.anderson@email.com
-  San Francisco, CA

SKILLS

- Patent Strategy
- Freedom-to-Operate Analysis
- Licensing Agreements
- Dispute Resolution
- Training Development
- Regulatory Compliance

LANGUAGES

- English
- Spanish
- French

EDUCATION

**MASTER OF SCIENCE IN
BIOTECHNOLOGY, UNIVERSITY OF
CALIFORNIA, BERKELEY**

ACHIEVEMENTS

- Negotiated a multi-million dollar licensing agreement that expanded market reach.
- Developed a proprietary tool for conducting patent landscape analyses.
- Received the Innovation Award for contributions to IP strategy.

PROFILE

An accomplished Biotechnology IP Analyst with a robust background in the intersection of law and biotechnology. Specializes in patent strategy formulation and execution, with a keen ability to identify and mitigate risks associated with IP assets. Extensive experience in conducting freedom-to-operate analyses, providing critical insights to support strategic decision-making. Proven track record of success in negotiating complex licensing agreements that foster innovation while maximizing revenue potential.

EXPERIENCE

BIOTECHNOLOGY IP COUNSEL

Bristol-Myers Squibb

2016 - Present

- Advised on patent strategy for new biotechnology products.
- Conducted freedom-to-operate analyses to support product launches.
- Drafted and negotiated licensing agreements with external partners.
- Managed disputes related to patent infringements and resolutions.
- Developed comprehensive training on IP rights for R&D teams.
- Collaborated with regulatory teams to ensure compliance with IP laws.

IP ANALYST

Gilead Sciences

2014 - 2016

- Performed patent landscape analysis to inform strategic planning.
- Assisted in the preparation of patent applications and responses to office actions.
- Maintained up-to-date knowledge of biotechnology patent law.
- Provided analytical support for patent litigation cases.
- Engaged with inventors to gather necessary documentation for filings.
- Produced reports on IP portfolio performance for executive review.